Investor attention is shifting toward a key scientific conference as shares of biotechnology firm Veru Inc. trade quietly. The company is scheduled to deliver multiple presentations on its lead drug ...

Certain men face a far greater risk of prostate cancer – yet many will still not be routinely offered testing under new ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...

Congress 2025 took place in Berlin, Germany, a dynamic epicentre known for its blend of innovation, culture, and historical ...

Actinium Pharmaceuticals, Inc. , a leader in the development of differentiated targeted radiotherapies, today announced compelling preclinical data for ATNM-400, a first-in-class Actinium-225 (AC-225) ...

A new research has revealed a clear association between chronic periodontitis and gynecological disorders such as PCOD and ...

The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...

近期，基于VISION[1] 和PSMAfore研究[2]的积极结果，国家药品监督管理局（NMPA）已批准镥 [177Lu]特昔维匹肽用于治疗前列腺特异性膜抗原（PSMA）阳性的 mCRPC 患者，覆盖了「ARPI + 化疗经治」和「ARPI ...

The importance of minority-interest remeasurement has expanded as joint venture and platform-licensing models become more common in biotech. For investors, such metrics provide an improved lens for ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute myeloid leukemia (AML), according to a new study by researchers at Penn ...

Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions ...